Benznidazole
 | |
| Systematic (IUPAC) name | |
|---|---|
|
N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide | |
| Clinical data | |
| Trade names | Rochagan, Radanil |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Bioavailability | High |
| Metabolism | Hepatic |
| Biological half-life | 12 hours |
| Excretion | Renal and fecal |
| Identifiers | |
| CAS Number |
22994-85-0  |
| ATC code | P01CA02 (WHO) |
| PubChem | CID 31593 |
| ChemSpider |
29299 |
| UNII |
YC42NRJ1ZD |
| KEGG |
D02489 |
| ChEMBL |
CHEMBL110 |
| Chemical data | |
| Formula | C12H12N4O3 |
| Molar mass | 260.249 g/mol |
| |
| |
| (verify) | |
Benznidazole (INN, formerly marketed by Hoffman-La Roche under the trade names Rochagan and Radanil) is an antiparasitic medication used in the treatment of Chagas disease. Its mechanism of action is the production of free radicals, to which the Trypanosoma cruzi is particularly sensitive given its reduced detoxification capabilities.[1] Roche donated the technology and rights to produce benznidazole to the Brazilian government.[2]
It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.[3]
Medical uses
Benznidazole has a significant activity during the acute phase of the disease, with a therapeutical success rate up to 80%. Its curative capabilities during the chronic phase are, however, limited. Some studies have found parasitologic cure (a complete elimination of T. cruzi from the body) in pediatric and young patients during the early stage of the chronic phase, but overall failure rate in chronically infected individuals is typically above 80%.[1]
However, some studies indicate treatment with benznidazole in chronic patients, even if incapable of producing parasitologic cure, carries a significative reduction of occurrence of electrocardiographic changes and a delayed worsening of the clinical condition of the patient.[1]
Benznidazole has proven to be effective in the treatment of reactivated T. cruzi infections caused by immunosuppression, such as AIDS patients or those under immunosuppressive therapy related to organ transplants.[1]
Side effects
The side effects most commonly associated with benznidazole therapy are rash and gastrointestinal symptoms such as nausea. Rarely, peripheral neuropathy may present after prolonged treatment.
References
- 1 2 3 4 Urbina, Julio A. "Nuevas drogas para el tratamiento etiológico de la Enfermedad de Chagas" (in Spanish). Retrieved March 24, 2012.
- ↑ http://www.itg.be/evde/04_Chagas_diseasep12.htm
- ↑ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
External links
- "Rochagan [Patient Information]" (PDF) (in Portuguese). Hoffmann-La Roche. Retrieved 2006-11-27. delete character in
|title=at position 10 (help)
| ||||||||||||||||||||||||||||||||||